Showing 1 - 7 results of 7 for search 'Sean M. O'Cathail', query time: 0.03s Refine Results
  1. 1
    Immune Checkpoint Inhibition as a Strategy in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer

    Immune Checkpoint Inhibition as a Strategy in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer by Catherine R. Hanna, Séan M. O’Cathail, Janet Graham, Richard Adams, Campbell S.D. Roxburgh

    Published 2021-05-01
    Get full text
    Article
  2. 2
    NRF2 Mediates Therapeutic Resistance to Chemoradiation in Colorectal Cancer through a Metabolic Switch

    NRF2 Mediates Therapeutic Resistance to Chemoradiation in Colorectal Cancer through a Metabolic Switch by Séan M. O’Cathail, Chieh-Hsi Wu, Rachael Thomas, Maria A. Hawkins, Tim S. Maughan, Annabelle Lewis

    Published 2021-08-01
    Get full text
    Article
  3. 3
    Patient-reported outcomes in PROSPECT trial (Alliance N1048) – FOLFOX is not a panacea

    Patient-reported outcomes in PROSPECT trial (Alliance N1048) – FOLFOX is not a panacea by Sean M. O'Cathail, Richard Adams, Maria A. Hawkins, David Sebag-Montefiore, Corrie A.M. Marijnen, Emmanouil Fokas

    Published 2023-11-01
    Get full text
    Article
  4. 4
    A Review of Scheduling Strategies for Radiotherapy and Immune Checkpoint Inhibition in Locally Advanced Rectal Cancer

    A Review of Scheduling Strategies for Radiotherapy and Immune Checkpoint Inhibition in Locally Advanced Rectal Cancer by Lydia Melissourgou-Syka, Michael A. Gillespie, Sean M. O'Cathail, Owen J. Sansom, Colin W. Steele, Campbell S. D. Roxburgh

    Published 2023-11-01
    Get full text
    Article
  5. 5
    The in-silico feasibility of dose escalated, hypofractionated radiotherapy for rectal cancer

    The in-silico feasibility of dose escalated, hypofractionated radiotherapy for rectal cancer by Lynsey Devlin, Laura Grocutt, Bianca Hunter, Hiwot Chemu, Aileen Duffton, Alec McDonald, Nicholas Macleod, Philip McLoone, Sean M. O'Cathail

    Published 2022-09-01
    Get full text
    Article
  6. 6
    A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR)

    A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced... by Séan M. O’Cathail, Steven Davis, Jane Holmes, Richard Brown, Kerry Fisher, Leonard Seymour, Richard Adams, James Good, David Sebag-Montefiore, Tim Maughan, Maria A. Hawkins

    Published 2020-06-01
    Get full text
    Article
  7. 7
    Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)

    Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT) by Catherine R. Hanna, Sean M. O’Cathail, Janet S. Graham, Mark Saunders, Leslie Samuel, Mark Harrison, Lynsey Devlin, Joanne Edwards, Daniel R. Gaya, Caroline A. Kelly, Liz-Anne Lewsley, Noori Maka, Paula Morrison, Louise Dinnett, Susan Dillon, Jacqueline Gourlay, Jonathan J. Platt, Fiona Thomson, Richard A. Adams, Campbell S. D. Roxburgh

    Published 2021-08-01
    Get full text
    Article

Search Tools: